Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2016-004491-22-DK
EUCTR2016-004491-22-DK
Active, not recruiting
Phase 1

Early detection of effects of chemotherapy in pancreatic cancer patients –a study using MR-hyperpolarization scanning based on hyperpolarized Pyruvate (13C) injection

Dept. Clinical Medicine, Aarhus Universit0 sites15 target enrollmentJanuary 3, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]MedDRA version: 20.0Level: LLTClassification code 10033575Term: Pancreas cancerSystem Organ Class: 100000004864

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
Sponsor
Dept. Clinical Medicine, Aarhus Universit
Enrollment
15
Status
Active, not recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 3, 2017
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Dept. Clinical Medicine, Aarhus Universit

Eligibility Criteria

Inclusion Criteria

  • •Inclusion criteria
  • •Patients with inoperable (metastatic, locally advanced or localised) histologically or cytologically verified pancreatic adenocarcinoma.
  • •Scheduled for first\-line palliative chemotherapy of any type.
  • •At least 18 years of age.
  • •WHO performance status 0\-2\.
  • •Measurable or unmeasurable disease.
  • •Adequate hematologic and organ function, i.e.
  • •ANC at least 1\.5
  • •Platlet count \>100
  • •Se bilirubin \<1\.5 UNL

Exclusion Criteria

  • •Patients in whom treatment is curatively intended, e.g. patients scheduled for preoperative treatment of marginally resectable disease
  • •Contraindications to contrast enhanced MRI
  • •Contraindication to contrast enhanced CT
  • •Not able or willing to receive chemotherapy
  • •Patients not willing to participate

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Not Applicable
Assessing the role of Positron Emission Tomography (PET) scanning to assess early response to treatment in advanced breast cancer.
ACTRN12612001044819Alfred Foundation5
Recruiting
Not Applicable
Early response evaluation of chemotherapy in malignant lymphoma by contrast-enhanced ultrasonography
JPRN-UMIN000024619ihon University School of Medicine, Itabashi Hospital50
Completed
Not Applicable
A prospective study of the effect of chemotherapy on metabolic and cardiovascular function in women with early stage breast cancerEarly stage breast cancerCancer - Breast
ACTRN12614001055695A/Prof Bogda Koczwara29
Completed
Phase 2
A trial of prospective adjuvant chemotherapy in patients with resectable colorectal cancer with heaptic metastasisResectable colorectal cancer with hepatic metastasis
JPRN-UMIN000014492Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine40
Active, not recruiting
Phase 1
Study evaluating the effects of chemotherapy on incurable cancer of the esophagus or stomachEsophagogastric adenocarcinomaMedDRA version: 18.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2014-000127-24-DKRigshospitalet, Department of Oncology98